Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Hoth Therapeutics has collaborated with Voltron Therapeutics to establish a joint venture (JV), HaloVax, for preclinical studies of vaccine candidates against Covid-19.
Vaccine candidates come from VaxCelerate self-assembling vaccine (SAV) platform, exclusively licensed by Voltron from the Massachusetts General Hospital (MGH)’s Vaccine and Immunotherapy Center (VIC).
Hoth Therapeutics and Voltron will work together to explore and develop SAV technology to fight the novel coronavirus infection.
VaxCelerate platform enables rapid development and pre-clinical testing of a new vaccine against specific pathogen targets. According to Hoth Therapeutics, the